Tenon Medical shareholders approve director elections, equity plan amendment, and Series B terms at 2024 annual meeting

Tenon Medical, Inc.

All seven director nominees elected with majority support; broker non-votes ~1.2M shares.
Shareholders approved Series B Preferred Stock terms and warrant issuance; vote 2,391,579 for, 45,130 against.
2022 Equity Incentive Plan amended to add 1,100,000 shares; approved 2,318,386 for, 117,137 against.
Haskell & White LLP ratified as independent auditor for FY2024; 3,609,093 for, 11,604 against.
Adjournment proposal approved to solicit additional proxies if needed; 2,720,153 for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.